- JCR aiming for '15 Japanese approval of Prochymal
- NAS in 2012: launch tally is century's best
- TiGenix 'remarkable' early stem cell success in rheumatoid arthritis
- Pluristem prices $32m offering to progress stem cell therapies
ONLY 0 DAY LEFT
|Stay close to your market. Renew online now to ensure uninterrupted access to:|
|SCRIP Intelligence's news and expert commentary|
|Market Data and Company Analysis (SCRIP 100, SCRIP Asia 100)|
|The Ask the Analyst Service...and more.|
Please remember to quote your order number and customer number.
You can also renew by calling: +44 (0)20 7017 5540.